LINE
Lineage, Inc. Common StockNASDAQREAL ESTATEREIT - INDUSTRIAL
Key Statistics
Market Cap
$10.25B
P/E Ratio
—
EPS
$-0.62
Beta
—
52W High
$44.36
52W Low
$30.81
50-Day MA
$36.44
200-Day MA
$37.66
Dividend Yield
5.28%
Profit Margin
-2.72%
Forward P/E
769.23
PEG Ratio
—
About Lineage, Inc. Common Stock
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.
Fundamentals
| Revenue (TTM) | $5.36B |
| Gross Profit (TTM) | $1.72B |
| EBITDA | $1.16B |
| Operating Margin | 3.32% |
| Return on Equity | -1.75% |
| Return on Assets | 0.80% |
| Revenue/Share (TTM) | $23.54 |
| Book Value | $35.61 |
| Price-to-Book | 1.15 |
| Price-to-Sales (TTM) | 1.91 |
| EV/Revenue | 3.225 |
| EV/EBITDA | 15.98 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.40% |
| Shares Outstanding | $227.67M |
| Float | $57.77M |
| % Insiders | 68.45% |
| % Institutions | 35.13% |
Historical Volatility
HV 10-Day
33.81%
HV 20-Day
41.99%
HV 30-Day
40.32%
HV 60-Day
41.22%
HV Rank
69.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($41.26 target)
1
Strong Buy4
Buy11
Hold4
Strong SellMore REAL ESTATE Stocks
Data last updated: 5/25/2026